Positron POSC
OTC POSC
$1.64 -0.05 (-2.96%)
At close: Nov 13, 2026 · 4:00 PM EST

Positron (POSC) EBT (2009 - 2026)

Updated

Positron (POSC) recorded EBT of -$821,400 in Q2 2026, compared with -$1.19 million a year earlier.

Analysis

Positron (POSC) EBT (2009 - 2026) Analysis & Trends

On a TTM basis, Positron's EBT came in at -$4.9 million as of Jun 30, 2026; for FY2025, it was -$10.59 million.

  • Across earlier years, EBT came in at -$2.35 million in FY2024.
  • The Q2 2026 figure is the highest quarterly EBT since Q4 2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT (Qtr)
1 Thermo Fisher Scientific 259.44 Bn 236.08 Bn 5.13 Bn 2.09 Bn
2 Abbott Laboratories 187.98 Bn 162.45 Bn 7.39 Bn 1.23 Bn
3 Danaher 163.91 Bn 143.58 Bn 3.84 Bn 1.13 Bn
4 Intuitive Surgical 153.75 Bn 134.17 Bn 2.08 Bn 668.40 Mn
5 Medtronic 131.67 Bn 97.80 Bn 6.34 Bn 1.77 Bn
6 Stryker 117.84 Bn 104.03 Bn 4.25 Bn 997.00 Mn
7 Boston Scientific 64.27 Bn 59.95 Bn 3.43 Bn 733.00 Mn
8 Edwards Lifesciences 61.69 Bn 45.00 Bn 1.35 Bn 363.20 Mn
9 Medline 51.94 Bn 49.07 Bn 1.93 Bn 386.00 Mn
10 Positron 54.28 Mn 48.07 Mn -389,441.00 -971,982.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 -971,982.00
Jun 30, 2026 -821,400.00
Mar 31, 2026 -1.38 Mn
Jun 30, 2025 -1.19 Mn
Mar 31, 2025 -1.51 Mn
Dec 31, 2024 -1.00 Mn
Sep 30, 2015 -255,000.00
Jun 30, 2015 -375,000.00
Mar 31, 2015 -554,000.00
Dec 31, 2014 -86,000.00
Sep 30, 2014 -1.44 Mn
Jun 30, 2014 -201,000.00
Mar 31, 2014 -861,000.00
Dec 31, 2013 -3.43 Mn
Sep 30, 2013 -1.39 Mn
Jun 30, 2013 -1.09 Mn
Mar 31, 2013 -1.20 Mn
Dec 31, 2012 -2.19 Mn
Sep 30, 2012 -1.57 Mn
Jun 30, 2012 -1.24 Mn
API Access

Positron EBT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebt&ticker=POSC&period=max&api_key=YOUR_API_KEY